BioSpace News Archive

File folder with Merger and Acquisition and financial graphs. Business concept

Deals

In Second Gene Therapy Buy of the Year, Novartis Acquires AveXis for $8.7B

Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.

April 9, 2018

·

3 min read

·

Mark

Small Cambridge Biotech Warp Bio Scores $387M R&D

Business

AstraZeneca Licenses NASH Drug from Ionis Worth a Potential $330+ Million

Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.

April 9, 2018

·

2 min read

·

Alex Keown

Close up picture of young man holding senior disabled woman's hand - blue bathrobe background

Biotech Beach

Acadia Pharmaceuticals Plunges Following Report that Links Nuplazid to High Number of Deaths

Shares of Acadia Pharmaceuticals are down more than 18 percent in premarket trading following a CNN report that raises concerns over a number of deaths and adverse events linked to the company’s Parkinson’s disease drug Nuplazid.

April 9, 2018

·

2 min read

·

Alex Keown

Woman celebrating her goals. Successful concept.

Drug Development

Merck’s Keytruda Grabs Another Late-Stage Clinical Win in Lung Cancer

Merck & Co. is chalking up another clinical win for its potent checkpoint inhibitor Keytruda. This morning the company announced the anti-PD-1 therapy hit its endpoints as a first-line monotherapy in lung cancer following an interim review of data.

April 9, 2018

·

2 min read

·

Alex Keown

A shot of a senior man sitting on the sofa with his daughter, looking at a photograph. He is cuddling his daughter, looking sad and holding the photo.

Doctor Calls for Alzheimer’s Boot Camps to Spur Drug Development

It’s no secret that drugmakers have struggled to develop a therapeutic to treat or halt the onset of Alzheimer’s disease. Multiple drugs have failed in late-stage trials and some companies, such as Pfizer, have largely given up on the space.

April 9, 2018

·

3 min read

·

Alex Keown

Why Novavax Could be a Millionaire-Maker Stock

Genetown

Magenta Therapeutics Snags $52 Million to Advance Bone Marrow Transplant Medications

Fresh off of striking a research deal with Ladenburg, Germany-based Heidelberg Pharma GmbH, Magenta Therapeutics secured $52 million.The funds will be used to advance Magenta’s portfolio of bone marrow transplant medications.

April 9, 2018

·

2 min read

·

Alex Keown

Drug Development

AbbVie’s Arthritis Drug Dazzles in Phase III Trial

AbbVie announced positive top-line data from its Phase III SELECT-COMPARE clinical trial of upadacitinib in moderate to severe rheumatoid arthritis.

April 9, 2018

·

3 min read

·

Mark Terry

Drug Development

Failed Clinical Trial: Menlo’s Stock Tanks

Menlo Therapeutics’ stock dropped 55 percent in premarket trading after announcing its serlopitant failed to meet primary and secondary endpoints in a Phase II clinical trial.

April 9, 2018

·

2 min read

·

Mark Terry